Clinical Trial Update: Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating combined PD-1 and CCR5 inhibition for refractory microsatellite-stable metastatic colorectal cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• PD-1 inhibitor + CCR5 inhibitor

Snippet

Sponsor: University Hospital Heidelberg | Conditions: Metastatic Colorectal Cancer, MSS | Phase 1 | Status: COMPLETED | Results posted: 2021-04-22